Why BioNTech Stock Sank by More Than 7% Today

A star stock during the pandemic era wasn't shining so brightly on Friday. On a media report that the current presidential administration is preparing to link a set of fatalities to Covid vaccines, BioNTech's (NASDAQ: BNTX) share price declined by 7% across that day's trading session. The biotech company's decline was particularly notable given the essentially flat-line performance of the S&P 500 index. That morning, The Washington Post published an article stating that healthcare officials in the Trump administration were aiming to link the deaths of 25 children to coronavirus vaccines. BioNTech is a co-developer of a top vaccine, Comirnaty, aimed at preventing the disease's spread (its partner in the effort was U.S. pharmaceutical giant Pfizer). Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool